Where medicine
begins as an idea.
220+ scientists. 6 research centers. One mission — turning molecules into affordable, life-saving therapies for patients across the globe.
Numbers that measure what we care about.
of annual revenue reinvested into R&D — well above the industry average.
ANDA & Dossier filings
Patents granted globally
Scientists & researchers
Dedicated R&D centers
Science that starts with the patient, not the molecule.
Patient-first pipeline
We prioritize unmet needs — pediatrics, chronic care, resistant infections.
AI-augmented discovery
Machine learning narrows candidate molecules from millions to dozens.
Global collaborations
Joint programs with universities in the UK, Germany, Singapore, and India.
Four divisions. One integrated pipeline.
Drug Discovery
Molecular design, target validation, and lead optimization for new chemical entities.
Formulation R&D
Turning APIs into tablets, injectables, and novel delivery systems.
Analytical R&D
Method development, validation, and stability testing across every dosage form.
Regulatory Affairs
Global dossier filing for USFDA, EU, WHO PQ, and 45+ national authorities.
Six centers. Three continents. One shared lab notebook.
Dhaka, Bangladesh
Formulation & ANDA hub
120 scientists
Cambridge, UK
Discovery & AI modeling
35 researchers
Frankfurt, Germany
Analytical excellence
28 chemists
Singapore
Biosimilar development
22 biologists
Hyderabad, India
API process research
40 engineers
Nairobi, Kenya
Tropical disease focus
18 field scientists
From idea to injection — a 7-year journey.
Discovery
12–18 months
Target ID, hit screening
Preclinical
18–24 months
Animal safety & PK
Formulation
12 months
Dosage form, stability
Clinical Trials
24–36 months
Phase I → III
Approval & Launch
6–12 months
Dossier, inspection
Where we're placing the biggest bets.
Biosimilars
Monoclonal antibodies for oncology and autoimmune care.
CNS Innovation
Novel formulations for epilepsy, depression, Alzheimer's.
Anti-Microbial Resistance
Reserve antibiotics and combination therapies.
Modified Release
Once-daily and long-acting delivery platforms.
Complex Injectables
Nanoparticles, liposomes, depot formulations.
Rare Diseases
Orphan drug development for underserved populations.
Equipment worth investing in.
We don't do great science alone.
University of Cambridge
AI drug design
ICDDR,B
Tropical disease research
NUS Singapore
Biosimilar co-development
Fraunhofer Institute
Analytical methods
BIRDEM Diabetes Institute
Clinical trial partner
WHO TDR
Neglected disease grants
Bangladesh ICDDR
Vaccine research
MRC Cambridge
Molecular biology
A year of firsts.
New product approvals
USFDA ANDAs filed
Peer-reviewed publications
New patents granted
"The best R&D isn't the one with the biggest budget. It's the one closest to the patient. That's why we invest here — in Dhaka, in Nairobi, in the places where breakthroughs actually matter."
Dr. Kamrul Hassan, PhD
Chief Scientific Officer
Certified where it counts.
Have an idea worth researching?
We partner with academic labs, biotech startups, and public health agencies. Bring us your science — we'll help scale it.